WHO: clinical trial of hydroxychloroquine in COVID-19 patients paused

The drug trial has been paused for safety concerns.

The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The US President has said he was taking the drug to help prevent infection.
"The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board," Tedros told an online briefing.
He said the other arms of the trial - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.
The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.
Dr. Mike Ryan, head of the WHO emergencies program, said the decision to suspend trials of hydroxychloroquine had been taken out of "an abundance of caution."
Defense Ministry to conduct exercise on Highway 35 on Sunday afternoon
Ukrainian drone attack on Moscow forces airport closure, Russia says
US condemns shooting of Colombian presidential candidate Miguel Uribe
Israeli man arrested in Albania after trying to leave with undeclared €194,000 - report
IDF Arabic Spokesperson Avichay Adraee issues evacuation notice to residents north of Gaza City
Fire breaks out in Haruvit Forest, not yet contained
France's Armed Forces Minister reaffirms no weapons being sold to Israel
IDF arrests PIJ Jenin Battalion commander during West Bank operation
Twenty live hostages, two undetermined, 33 dead, says Israeli source
North Korea internet hit by a major outage, analyst says